LAX.SH
LAURUS LABS LIMITED·PHARMACEUTICALS 72.79CDMO 65.70·Pharmaceuticals & Biotechnology Companies
Price
1,507.4
+2.6%52W Range
Market Cap
₹81,377.98 Cr
Traded: ₹307.38 Cr (0.38%) 0.0x
Free Float: ₹21,613.99 Cr (1.42% of FF traded)
Volume · 60D trend
20.35 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +17.0% | +15.0% | +10.0% | -- | -- | Decelerating |
| Return | -- | +19.0% | +53.0% | +82.0% | -- | Accelerating |
| Sales | +14.0% | +7.0% | +4.0% | -- | +23.0% | Stable |
| Profit | +21.0% | -2.0% | +4.0% | -- | +178.0% | Accelerating |
Quarterly Results
Mar 2026
30 AprDec 2025
23 JanSep 2025
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,812 | 1,778 | 1,653 | 1,570 | 1,720 | 1,415 | 1,224 | 1,195 | 1,440 | 1,195 | 1,224 | 1,182 | 1,381 | 1,545 |
| Expenses | 1,299 | 1,298 | 1,250 | 1,187 | 1,300 | 1,130 | 1,045 | 1,024 | 1,198 | 1,014 | 1,037 | 1,015 | 1,095 | 1,141 |
| Operating Profit | 512 | 480 | 403 | 382 | 421 | 285 | 178 | 171 | 241 | 181 | 188 | 167 | 286 | 404 |
| OPM % | 28.0% | 27.0% | 24.0% | 24.0% | 24.0% | 20.0% | 15.0% | 14.0% | 17.0% | 15.0% | 15.0% | 14.0% | 21.0% | 26.0% |
| Other Income | 12 | 6 | 27 | 10 | 59 | 9 | 5 | 3 | 19 | 2 | 2 | 4 | 2 | 1 |
| Interest | 40 | 39 | 40 | 52 | 56 | 58 | 53 | 49 | 50 | 51 | 42 | 39 | 53 | 43 |
| Depreciation | 122 | 121 | 120 | 117 | 110 | 106 | 108 | 106 | 102 | 98 | 93 | 91 | 87 | 84 |
| Profit Before Tax | 361 | 327 | 270 | 224 | 312 | 131 | 23 | 18 | 107 | 35 | 54 | 41 | 147 | 278 |
| Tax % | 22.0% | 22.0% | 28.0% | 28.0% | 25.0% | 31.0% | 22.0% | 34.0% | 30.0% | 27.0% | 27.0% | 30.0% | 27.0% | 27.0% |
| Net Profit | 282 | 252 | 194 | 162 | 233 | 93 | 20 | 13 | 75 | 23 | 37 | 27 | 105 | 203 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 5.2 | 4.7 | 3.6 | 3.0 | 4.3 | 1.7 | 0.4 | 0.2 | 1.4 | 0.4 | 0.7 | 0.5 | 1.9 | 3.8 |
| Sales Growth (YoY) | 5.3% | 25.6% | 35.0% | 31.4% | 19.4% | 18.4% | 0.0% | 1.1% | 4.3% | -22.6% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 1.9% | 7.6% | 5.3% | -8.7% | 21.6% | 15.6% | 2.4% | -17.0% | 20.5% | -2.4% | 3.5% | -14.4% | -10.6% | -- |
| OP Growth (YoY) | 21.6% | 68.4% | 126.4% | 123.4% | 74.7% | 57.5% | -5.3% | 2.4% | -15.7% | -55.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | 6.7% | 19.1% | 5.5% | -9.3% | 47.7% | 60.1% | 4.1% | -29.0% | 33.1% | -3.7% | 12.6% | -41.6% | -29.2% | -- |
| Profit Growth (YoY) | 19.0% | 173.0% | 883.0% | 1203.0% | 209.0% | 299.0% | -46.0% | -50.0% | -27.0% | -89.0% | -84.0% | -90.0% | -55.0% | 32.0% |
| EPS Growth (YoY) | 19.4% | 172.5% | 875.7% | 1213.0% | 209.3% | 297.7% | -46.4% | -50.0% | -26.7% | -88.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 10.9% | 29.1% | 19.5% | -30.3% | 153.2% | 362.2% | 60.9% | -83.6% | 225.6% | -37.7% | 50.0% | -75.9% | -49.3% | -- |
| OP Margin | 28.3% | 27.0% | 24.4% | 24.3% | 24.5% | 20.1% | 14.5% | 14.3% | 16.7% | 15.2% | 15.4% | 14.1% | 20.7% | 26.1% |
| Net Margin | 15.6% | 14.2% | 11.7% | 10.3% | 13.6% | 6.6% | 1.6% | 1.1% | 5.2% | 1.9% | 3.0% | 2.3% | 7.6% | 13.1% |
| Material Cost % | -- | 39.1% | 40.1% | 40.6% | 45.5% | 43.1% | 44.8% | 44.9% | 50.1% | 45.6% | 47.5% | 49.4% | 50.3% | 46.6% |
| Employee Cost % | -- | 12.9% | 13.0% | 13.7% | 10.3% | 13.4% | 14.6% | 14.6% | 11.2% | 13.0% | 13.4% | 13.5% | 9.7% | 9.5% |
| P/S | 11.94 | 8.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 91.58 | 70.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 15.35 | 12.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please see annexed enclosure.
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Please see annexed annexure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see enclosed annexure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see enclosed annexure
Please see annexed enclosure
Please see enclosed annexure
Please see enclosed annexure
Please see annexed enclosure
Please see enclosed annexure
Please see enclosed annexure
Please see enclosed annexure
Please see enclosed annexure
Please see annexed
Please see enclosed annexure
Please see annexed enclosure.
Please see annexed enclosure.
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 ,inter alia, to consider and approve the Audited Financial Results For ....
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure
Please see annexed enclosure
Please see enclosed annexure
Please see annexed enclosure.
Please see annexed enclosure
Please see annexed enclosure.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund
Please see enclosed annexure
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure
Please see enclosed annexure
Annual Reports
12Credit Ratings
6Concalls
43Jan 2026
31 Jan 2026Oct 2025
31 Oct 2025Sep 2025
30 Sept 2025Jul 2025
31 Jul 2025Apr 2025
30 Apr 2025Jan 2025
31 Jan 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Jul 2024
31 Jul 2024Apr 2024
30 Apr 2024Jan 2024
31 Jan 2024Nov 2023
30 Nov 2023Oct 2023
31 Oct 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Oct 2022
31 Oct 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Mar 2022
31 Mar 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Dec 2020
31 Dec 2020Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020May 2020
31 May 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Nov 2018
30 Nov 2018Aug 2018
31 Aug 2018May 2018
31 May 2018Jan 2018
31 Jan 2018Nov 2017
30 Nov 2017Aug 2017
31 Aug 2017May 2017
31 May 2017Feb 2017
28 Feb 2017Held by ETFs
38 ETFs hold lauruslabs · sorted by weight
Held by Mutual Funds
7 schemes hold lauruslabs · sorted by weight